Abstract -Substantial advances in improving human cancer treatment continue to require discovery and development of new and curative anticancer drugs. Our recent progress in discovery and development of new anticancer drugs derived from marine animal and terrestrial plant biosynthetic products has been reviewed. Special emphasis was placed upon the bryostatin (1,2), dolastatin (4-6), halichondrin (15), halistatin (16,17), spongistatin (18-20), cephalostatin (7-14) and pancratistatin (34) series of potentially useful anticancer drugs.
The U. S. National Cancer Institute (NCI) research programs directed at discovery of new and clinically important animal, plant, and microorganism anticancer constituents were implemented in 1957 and have amply demonstrated that 2-4% of plant species and some 10% of marine animal species contain a great variety of antineoplastic and/or cytotoxic (ref. 8-18 ) constituents. The dramatic discoveries arising from the NCI research, such as taxol, (ref. 14,15) have stimulated considerable world-wide interest and initiation of analogous programs.
Because of this vitally important NCI endeavor, new antineoplastic and/or cytotoxic biosynthetic products are being discovered at an increasing rate. The potential for discovering new animal, plant and microorganism biosynthetic products for treatment of human cancer is truly immense and offers great promise of many curative approaches to the cancer problem. Consider that the world's flora may number up to 800,000 and the more conspicuous terrestrial vegetation, the angiosperms, may number from 300,000 to some 500, 000 (ref. 16 ). Furthermore, enormous numbers of marine animal (over 2,000,000) and microorganism species (ref. 17) are available for investigation. Even now, less than 10% of the higher plants and less than 0.5% of the marine animals (ref. [8] [9] [10] ) have received even a cursory effort to detect antineoplastic constituents. So the majority of important animal and plant cancer chemotherapeutic drugs still await discovery.
In 1965-66 we began the first systematic study of marine invertebrates and vertebrates as potential sources of new and potentially useful cancer chemotherapeutic drugs (ref. 18) . reproducible (confirmed active) antineoplastic activity in the NCI murine P388 in vivo lymphocytic leukemia screening system. Froill this evidence, it was abundantly clear that such natural products present an unusually good opportunity for discovering clinically useful anticancer drugs. To date we have isolated a large number of new cytotoxic and/or antineoplastic agents from marine animals.
Discovery (ref. 1) of the bryostatin series of marine Bryozoa constituents represents an especially important advance for the future and bryostatin 1 (1) has been undergoing ability to influence protein kinase C which mediates one arm of a major signal transduction pathway involving lipophilic secondary messengers. We have been able to deduce (ref. 2 2 ) the absolute configuration of the bryostatins, convertbryostatin 2 ( 2 ) chemically to bryostatin 1 and related bryopyrans (ref. (ref. 3 3 , 3 4 ) . In general, bryostatin 1 was found to be a B-cell differentiating agent with a potential therapeutic role in treatment of such lymphomas (ref. 3 5 , 3 6 ) . Indeed, the early potential of bryostatin 1 with its immunomodulatory and antineoplastic properties as a biological response modifier is already being realized in clinical trials. Interestingly, bryostatin 1 has been found to potentiate ARA-C apoptosis o r programmed cell death, and this combination looks very promising for clinical evaluation (ref. 3 7 , 3 8 , 3 9 , 4 0 Among the many animal o r in vitro experiments conducted with the bryostatins, the potential of one has already been realized in the clinic ( ref. 19) , namely the ability of bryostatin 1 to reverse murine B16 melanoma pulmonary metastases (ref. 4 2 ) . Another nice advance that will eventually be tested in the clinic involves its use in adoptive immunotherapy (ref. In other murine experiments, bryostatin 1 has proved to be dramatically (1 pg/mouse) effective against lethal whole body irradiation producing a 70% survival rate that increased to about 80% using coadministered GM-CSF (ref. 4 4 ) . Another 19 research publications involving more fundamental research with bryostatin 1 in various cell systems will now be just cited (ref. 4 5 -6 3 ) . In short, the bryostatin research has been very productive and stimulated much world-wide interest. From all appearances, bryostatin 1 and eventually perhaps other members in the series will become successful anticancer drugs, in addition to their already well established role as unique biochemical probes. Dolastatin 10 ( 4 ) continues to be a high priority clinical development objective by the NCI and European collaborators. Our challenging isolation and structural elucidation research with shell-less mollusks such as Dolabella auricularia has continued and resulted in discovery of the strong cell growth inhibitor dolastatin 1 4 ( 5 ) (ref. 6 4 ) along with further chemical and antineoplastic studies of dolastatins 10-15 (ref. 6 5 ) . In order to provide sufficient quantities of dolastatins 10 ( 4 ) and 15 (6) for clinical development, an intense research effort was devoted to these vital total synthetic objectives, (ref. 6 6 -7 0 ) and include our new and more stereoselective total synthesis of dolastatin 10. We have also improved our initial total synthesis of dolastatin 15 (ref. 7 1 ) . At the same time, an extensive series of structure/activity investigations using total synthetic approaches have been underway and reference 7 2 provides an illustration. Dolabella a. continues to yield new antineoplastic substances along with the first example of the nickel chelate, tunichlorin, occurring in a mollusc (ref. 7 
) .
A large number of biological experiments are being conducted with dolastatins 10 and 15.
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H Among these studies, dolastatins 10 and 15 were found to inhibit proliferation of human leukemia cell lines at concentrations lower than those that inhibited the growth of normal cells (ref. Those dramatic results combined with the need for preclinical supplies of cephalostatins 1 (8) and 7 (7) necessitated a 450 kg recollection of this tiny (less than 5 nun) Indian Ocean (Southeast Africa) worm. Because of the substantial (and challenging) research effort here, we discovered new cephalostatins 10 (9) and 11 (10, ref. 83 ), cephalostatins 12 (11) and 13 (12, ref. 84 ) and cephalostatins 14 (13) and 15 (14, ref. 85) . As usual in this series, the structural determinations were difficult but the extraordinary and selective effects against various human cancer cell lines in the NCI panel have been very rewarding. Presently, several of the newer cephalostatins appear to compete quite falrorably with cephalostatins 1 (8) and 7 (7) in terms of cancer cell growth inhibition. We have detected the presence of several more new cephalostatins that will extend the series and provide additional useful structure/activity relationship information. The new cephalostatins occur in yields of about lo-*% and give every evidence of being exceptionally potent. The preliminary activity against brain cancer xenografts provides a good basis for the difficult research in progress here. h A
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recollection that recently led us to 10.7 mg (4.4 x lo-'% yield) of spongistatin 4 These three compounds proved to be among the most potent of all substances tested to date in the NCI panel. Interestingly, several of the human breast cancer cell lines recently incorporated into the NCI panel were among the most sensitive (e.g., GI50 10-11-10-12M). Furthermore, results of pattern-recognition analyses revealed that the highly distinctive mean-graph "fingerprint" (pattern of relative cellular sensitivity) produced in common by spongistatins 1 (18) and 5 (20) is closely correlated to the important class of microtubule-interactive antimitotics. Among the major objectives for continued research with the spongistatins will be completing an X-ray crystal structure determination to establish the stereochemistry at each asymmetric center and the absolute configuration.
In our more recent investigations of marine Porifera antineoplastic constituents, we discovered the murine P388 lymphocytic leukemia cell growth inhibitor and cyclooctapeptide hymenistatin 1 (21) which represented the first such combination of source, structural type, and biological activity (ref, 90) .
Isolation and characterization of such a seemingly unexceptional cyclic peptide with cell growth inhibitory properties provides a new insight into structure requirements for antineoplastic activity (hymenistatin 1 also inhibits growth of the P388 system in vivo). That advance allowed us to concentrate on discovery of new marine animal cyclic peptides with antineoplastic activity.
The novel substances we are presently investigating are providing considerable insights into structural requirements for antineoplastic activity among sponge cyclic peptide constituents. Illustrative is our isolation and structural elucidation of stylostatin 1 ( ref. 94,95,96) . All of these very interesting and potentially useful new marine animal cyclic peptides have been found to exhibit moderate to strong cancer cell growth inhibition ranging from GIs0 0.1 to 0.001 pg/ml. The structures were all assigned on the basis of high field ( 4 0 0 and 500 MHz) 2D-NMR, high resolution MS/MS tandem type mass spectrometry, X-ray crystallography and chiral gas chromatographic analyses of hydrolysis products.
Another productive advance with marine porifera antineoplastic constituents was discovery of cribrostatins 1 and 2 (30,31) in a blue sponge we uncovered in the Republic of Maldives (ref. 104). These latter experiments led to a dramatic result: pancratistatin was found to be the first substance to cure Japanese encephalitis in an experimental animal (ref. 104) . Other research has been focused on devising an efficient total synthesis of pancratistatin. Among the many isolation, synthetic and antineoplastic evaluations (ref. 105) we have been pursuing to advance the combretastatin A-4 (37) lead has been successful synthesis of a water soluble pro-drug and the isolation and structure determination of combretastatin D-2 ( 3 8 , ref. 106) .
The surprisingly strong and selective activity of combretastatin A -4 against unusually difficult human cancer cell types continues to be very impressive (ref. 105 ).
In the general area of terrestrial plant cell growth inhibitory and/or antineoplastic constituents, discoveries as diverse as lychnostatins 1 and 2 ( 3 9 , ref. 107) In summary, the foundation is now available for a rapid acceleration in the discovery of new animal, plant and microorganism derived anticancer and antiviral drugs. That vitally necessary objective will continue to guide our future research endeavors.
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